Home Tags Takeda

Tag: Takeda

Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...

Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...

Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...

Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...

Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...

Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...

ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...

Takeda and Maverick Therapeutics Develop Novel Biologics Platform to Advance T-Cell...

Maverick Therapeutics, a private start-up biotechnology company that had been solely financed by MPM Capital when it was spun out of its former parent,...

Patient Enrollment in Phase III ECHELON-2 Clinical Trial of Brentuximab Vedotin...

This week, Seattle Genetics and Takeda Pharmaceutical Co. confirmed that enrollment in the ECHELON-2 clinical trial, a global phase III randomized trial evaluating brentuximab vedotin...

ISHL 2016: Seattle Genetics Commits to Improving Hodgkin Lymphoma Treatment

In a pre-conference announcement before the start of 10th International Symposium on Hodgkin Lymphoma (ISHL) taking place at the Gürzenich in Cologne, Germany, October 22-25,...

Takeda and Crescendo Collaborate to Generate Tumor Targeting Drug-conjugates and Immuno-oncology...

Crescendo Biologics, based in Cambridge, UK, the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company announced a global, strategic, multi- target...
Woman Having Chemotherapy With Nurse Using Digital Tablet

INSIGHT-MM Study Designed to Advance Real-world Understanding of Multiple Myeloma

In late Augustus 2016 Takeda Oncology announced that the INSIGHT-MM, the company's global non-interventional, observational multiple myeloma study, is now enrolling patients. The study...

DOWNLOAD